Navigation Links
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Date:12/4/2007

sored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended September 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Ph
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... LAVAL, Quebec , March 27, 2015  Valeant ... announced today the closing of its previously announced registered ... States (the "Offering"). Pursuant to the Offering, ... of $199.00 per share, for aggregate gross proceeds of ... filed with the U.S. Securities and Exchange Commission a ...
(Date:3/27/2015)... March 27, 2015  RXi Pharmaceuticals Corporation ... LLC, today announced that they have entered ... novel and proprietary sd-rxRNA® technology for use ... collaboration has the potential to result in ... treatments that could be a significant step ...
(Date:3/27/2015)... 27, 2015  WebMD Health Corp. (NASDAQ: ... health information, today announced an exclusive White ... Action Plan for Combating Antibiotic-Resistant Bacteria . ... urgency and importance of addressing antibiotic-resistant bacteria ... health.    The WebMD interview, available ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... , , , ... leading developer of medical device technology for the safe ... new Webinar program supporting its culture of safety initiative ... "A Culture of Safety in Pharmacy: Lessons Learned," features ...
... , MOUNTAIN VIEW, Calif., Dec. 29 VIVUS, Inc. (Nasdaq: ... therapies to address unmet needs in obesity, diabetes and sexual ... been submitted to the U.S. Food and Drug Administration (FDA) ... of obesity, including weight loss and maintenance of weight loss, ...
Cached Medicine Technology:Baxa Corporation to Sponsor Free Culture of Safety Webinar 2Baxa Corporation to Sponsor Free Culture of Safety Webinar 3VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 2VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 3VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 4VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 5
(Date:3/27/2015)... 27, 2015 On February 21, ... in the Stardust Penthouse on the rooftop of ... Angeles’ leading sustainable product TV and film placement ... day-long event, which featured some of the world’s ... products and services. , “We were honored to ...
(Date:3/27/2015)... March 27, 2015 According to a ... ), the plate and screw market in Europe is ... generic plate and screw segment. Price decreases are being ... representing almost 50% of the total European trauma device ... the total market value, year after year. , ...
(Date:3/27/2015)... 2015 According to Health Day ... with Neonatal Abstinence Syndrome (NAS) are causing alarm for ... painful withdrawal process for a month of their lives- ... diarrhea, and vomiting. The condition is precipitated by drug ... addiction treatment (and employing medically assisted drug treatment) will ...
(Date:3/27/2015)... March 27, 2015 When struck with ... hard to know where to begin. The latest ... trucking accident attorney, offers accident victims a clear and ... assistance to ensure their personal injury claim is seen ... describing the first actions that should be taken immediately ...
(Date:3/27/2015)... Texas (PRWEB) March 27, 2015 ... Glutathione Industry is a professional and in-depth study ... glutathione market with a focus on the ... overview of the industry including definitions, classifications, applications ... is provided for both the international and Chinese ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3
... nutritional supplements ... in North ... Alliance,(CWA), experts in designing custom wellness programs for consumers and,corporations, ... announcement was made by biochemist, Lyle MacWilliam, author,of the recently ...
... many,people who have called and asked how they could help, ... with Tony Snow,s children,s education and,expenses., Jill Snow, Tony,s ... Kendall, Robbie and Kristi, as beneficiaries. Donations can,be made directly ... check,made payable to the "Tony Snow Family Trust" to:, ...
... ANGELES, July 14 The Cooperative of American,Physicians, ... exceeded 10,000 physicians., "Surpassing the 10,000 member ... CEO James L. Weidner. "The physicians who founded,CAP ... They believed that,physicians working together could find a ...
... with upbeat outlook, but same did not hold true for women ... had a lower risk of dying from heart disease turned out ... their conventional risk factors showed. , The death rate for men ... of those who listed themselves as being at average risk, said ...
... The Medical Device,Manufacturers Association (MDMA), a national trade ... the Board of Directors at the,MDMA Annual Meeting ... http://www.newscom.com/cgi-bin/prnh/20041004/MDMALOGO ), "I am honored to ... Manufacturers,Association," stated Root. "MDMA has a long history ...
... in heart and travels to the brain, heparin more risky, ... widely prescribed blood-thinning drug heparin is associated with an increased ... cardioembolic stroke, new research shows. , But another thinning ... in the same group of patients. , This finding led ...
Cached Medicine News:Health News:Vitalize(TM) Receives Top Multivitamin Rating 2Health News:Cooperative of American Physicians Membership Tops 10,000 2Health News:Optimism About Heart Risk Pays Off 2Health News:Vascular Solutions CEO Elected to MDMA Board of Directors 2Health News:Warfarin Safer Than Heparin for Some Strokes 2
... Full frontal protection, our conventional ... shoulders by sturdy 2 webbed ... quick-acting snap hook fasteners. The ... custom fit the apron. Our ...
Unshielded...
... The Triage BNP Test is ... Blood test measuring B-type natriuretic peptide ... heart ventricles in response to ventricular ... hormonal marker of ventricular systolic and ...
... The MOST Options System is designed ... loss of the knee or hip ... and provides the potential for restoration ... beyond the requirements of a rotating ...
Medicine Products: